[어바웃 C] 오름테라퓨틱, 마리아 콜러 신임 보드멤버 선임의 의미

Arum Therapeutics is restructuring its board to support a critical transition: from a licensing-focused business model to one anchored in clinical advancement and strategic partnerships. The company's revenue model—historically dependent on upfront payments and milestones from asset licenses—now depends on advancing internally-developed DAC candidates to clinical trials and securing high-value partnerships. This governance shift reflects the market's understanding that biotech companies at Arum's stage need both clinical development expertise and partnership acumen to unlock the next level of value creation.